KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biomarin Pharmaceutical (BMRN) Other Operating Expenses (2016 - 2025)

Biomarin Pharmaceutical's Other Operating Expenses history spans 17 years, with the latest figure at $1.0 million for Q4 2025.

  • For the quarter ending Q4 2025, Other Operating Expenses rose 114.92% year-over-year to $1.0 million, compared with a TTM value of $5.9 million through Dec 2025, up 225.49%, and an annual FY2025 reading of $9.0 million, up 292.74% over the prior year.
  • Other Operating Expenses for Q4 2025 was $1.0 million at Biomarin Pharmaceutical, down from $4.8 million in the prior quarter.
  • The five-year high for Other Operating Expenses was $9.1 million in Q3 2021, with the low at -$19.9 million in Q4 2023.
  • Average Other Operating Expenses over 5 years is -$2.9 million, with a median of -$817000.0 recorded in 2023.
  • Year-over-year, Other Operating Expenses tumbled 1103.38% in 2023 and then soared 768.67% in 2024.
  • Tracing BMRN's Other Operating Expenses over 5 years: stood at -$10.4 million in 2021, then grew by 8.48% to -$9.6 million in 2022, then tumbled by 108.27% to -$19.9 million in 2023, then soared by 65.47% to -$6.9 million in 2024, then soared by 114.92% to $1.0 million in 2025.
  • Per Business Quant, the three most recent readings for BMRN's Other Operating Expenses are $1.0 million (Q4 2025), $4.8 million (Q2 2025), and -$6.9 million (Q4 2024).